Jaden Evans, MD
Radiation Oncology · Ogden, UTNPI 1881075018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by IBA Proton Therapy, Inc. at 28.5% of the total. 2025 is the largest year on record at $481, more than ten times the $12 reported in 2019.
Across 29 payments — averaging $30.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- IBA Proton Therapy, Inc.$252
- Boston Scientific$195
- Progenics Pharmaceuticals, Inc.$71
- Sumitomo Pharma America, Inc.$69
- Pfizer$53
- Novocure Inc.$51
- plus $192 from 8 others
What the payments were for
- Food & beverage$884100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| IBA Proton Therapy, Inc. | 1 | $252 |
| Boston Scientific | 6 | $195 |
| Progenics Pharmaceuticals, Inc. | 3 | $71 |
| Sumitomo Pharma America, Inc. | 3 | $69 |
| Pfizer | 3 | $53 |
| Novocure Inc. | 3 | $51 |
| Novartis | 2 | $40 |
| Myovant Sciences Inc. | 2 | $33 |
| Dendreon Pharmaceuticals LLC | 1 | $29 |
| Bioprotect Medical, Inc. | 1 | $29 |
| Tactile Systems Technology Inc | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
| Blue Earth Diagnostics | 1 | $12 |
How this compares
$884 in reported general payments places this provider in the 70th percentile of 49 radiation oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 74 | $1,249 |
| Solifenacin Succinate | 22 | $571 |
| Ciprofloxacin Hcl | 15 | $53 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Ogden
- Gary WhippleOgden$807
- Roger HansenOgden$783
- Chase HansenOgden$760
- Brandon FisherOgden$397
- Jonathan TwardSalt Lake City$114K
- David GaffneySalt Lake City$22K
- Brandon BarneyAmerican Fork$16K
- Douglas HoltSalt Lake City$3K
- Kristine KokenySalt Lake City$3K
- Matthew PoppeSalt Lake City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.